OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/09/26	JP¥22.00	0.00%	146,689,000
16/09/26	JP¥22.00	-4.35%	180,740,600
15/09/26	JP¥23.00	+4.55%	180,110,600
14/09/26	JP¥22.00	-4.35%	168,259,100
11/09/26	JP¥23.00	+4.55%	165,706,200

Delayed Quote Japan Exchange

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange 14:30:00 17/09/2026 HKT			5-day change	1st Jan Change
22.00 ^JPY	0.00%		-4.35%	+10.00%

24/06/25	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt	CI
28/04/25	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited	CI

Market Cap	8.98B 57.64M 50.21M 47.52M 43.17M 80.65M 5.52B 81.05M 566M 219M 2.81B 217M 212M	P/E 2025	-8.97x	P/E 2026	-7.57x
Enterprise Value	6.89B 44.24M 38.53M 36.47M 33.13M 61.89M 4.24B 62.2M 434M 168M 2.15B 166M 162M	EV / Sales 2025	9.03x	EV / Sales 2026	7.39x
Free-Float	88.54%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
Japan Exchange	4564	Delayed
Deutsche Boerse AG	30O	Delayed
Boerse Muenchen	30O	Real-time

24/06/25	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt	CI
28/04/25	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited	CI
10/04/25	OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding	CI
29/04/24	Poland's Tusk calls prosecutor over potential Orlen scandal	RE
22/04/24	OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024	CI
05/04/24	OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investor	CI
18/09/23	OncoTherapy Science, Inc.(TSE:4564) dropped from S&P Global BMI Index	CI
12/05/23	OncoTherapy Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
10/04/23	OncoTherapy Science, Inc. announced that it has received ¥95.95 million in funding	CI
24/03/23	OncoTherapy Science, Inc. announced that it expects to receive ¥95.95 million in funding	CI
28/04/21	OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	CI
12/04/21	OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	CI
15/01/19	OncoTherapy Science, Inc. announced that it has received ¥12.013 million in funding from Daiwa Securities Group Inc.	CI

OncoTherapy Science, Inc. Stock

Stocks

4564

JP3202150003

Biotechnology & Medical Research

Valuation: OncoTherapy Science, Inc.

Chart: OncoTherapy Science, Inc.

Latest news: OncoTherapy Science, Inc.

Press Releases: OncoTherapy Science, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: OncoTherapy Science, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

14/05/24	Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	AQ
05/12/23	Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	AQ
13/09/22	OncoTherapy Science : Announcement of the Presentation of Interim Results for Phase I Clinical Study of a Combination of OTSGC-A24 and Immune Checkpoint Inhibitor in Patients with Gastric Cancer	PU
01/10/20	OncoTherapy Science : Japanese bio-venture starts development of COVID-19 peptide vaccine	AQ

1 week	-4.35%
1 month	+10.00%
3 months	+15.79%
6 months	-4.35%
Current year	+10.00%

Manager	Title	Age	Since
Junichi Shimada PSD	President	65	01/07/2022
Zehyon Paku PSD	President	50	05/12/2019
Yuka Yamane CTO	Chief Tech/Sci/R&D Officer	53	01/08/2012

Director	Title	Age	Since
Yuichi Komine BRD	Director/Board Member	54	01/09/2014
Zehyon Paku BRD	Director/Board Member	50	01/06/2018
Hatsuo Kato CHM	Chairman	82	01/06/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCOTHERAPY SCIENCE, INC.	0.00%	-4.35%	-15.38%	-26.67%	57.91M
WUXI APPTEC CO., LTD.	+1.76%	+3.62%	+49.92%	+101.12%	69.69B
ARGENX SE	+2.29%	+1.43%	+38.39%	+77.80%	61.24B
INSMED INCORPORATED	+0.62%	-2.98%	-14.71%	+365.12%	26.77B
WUXI BIOLOGICS (CAYMAN) INC.	+0.32%	+2.58%	+29.26%	+14.12%	26.12B
BIONTECH SE	+2.86%	+2.16%	+0.34%	-9.68%	24.07B
GENMAB A/S	+1.49%	+7.73%	+26.85%	-13.79%	20.39B
PHARMAESSENTIA CORPORATION	-0.83%	-11.15%	+169.70%	+295.44%	15.72B
EXELIXIS, INC.	+1.98%	+0.84%	+43.21%	+171.26%	14.07B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.17%	-4.07%	-9.71%	+484.05%	14.03B
Average	+1.08%	-1.50%	+31.79%	+145.88%	27.22B
Weighted average by Cap.	+1.49%	+0.20%	+36.36%	+129.64%

	2025	2026
Net sales	750M 4.81M 4.19M 3.97M 3.61M 6.74M 461M 6.77M 47.26M 18.28M 234M 18.08M 17.68M	808M 5.19M 4.52M 4.27M 3.88M 7.26M 497M 7.29M 50.92M 19.69M 252M 19.48M 19.05M
Net income	-815M -5.23M -4.56M -4.31M -3.92M -7.32M -501M -7.35M -51.36M -19.86M -255M -19.65M -19.21M	-910M -5.84M -5.09M -4.81M -4.37M -8.17M -559M -8.21M -57.35M -22.17M -284M -21.94M -21.45M
Net Debt	-833M -5.35M -4.66M -4.41M -4M -7.48M -512M -7.52M -52.49M -20.3M -260M -20.08M -19.64M	-2.09B -13.41M -11.68M -11.05M -10.04M -18.76M -1.28B -18.85M -132M -50.9M -653M -50.37M -49.25M